HRS 2020: Medtronic’s Pacemaker Monitoring App Proves Reliable In BlueSync Study
The BlueSync Evaluation study showed pacemaker patients using the MyCareLink Heart mobile device app were able to stick to their prescribed transmission schedule more often than patients using beside consoles.
You may also be interested in...
An expert panel at the recent AdvaMed Virtual Digital MedTech Conference discusses opportunities for medtech and consumer tech collaborations and how to make them successful.
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.